<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551612</url>
  </required_header>
  <id_info>
    <org_study_id>Patients with Cholesteatoma</org_study_id>
    <nct_id>NCT04551612</nct_id>
  </id_info>
  <brief_title>Level of Middle Cranial Fossa Dura in Patients With Cholesteatoma</brief_title>
  <official_title>Evaluation of the Level of Middle Cranial Fossa Dura in Patients With Cholesteatoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholesteatoma is a destructive lesion that progressively expands in the middle ear, mastoid&#xD;
      or petrous bone and leads to destruction of the nearby structures. Erosion, which is caused&#xD;
      by bone resorption of the ossicular chain and otic capsule, may cause hearing loss,&#xD;
      vestibular dysfunction, facial paralysis and intracranial manifestations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholesteatoma has three Classical forms: (1) Congenital, primary or genuine cholesteatoma:&#xD;
      occurs behind an intact tympanic membrane. Primary acquired cholesteatoma: looks like a&#xD;
      limited diverticulum of the pars flaccida with little or no history of otorrhea. Secondary&#xD;
      acquired cholesteatoma: develops with posterosuperior perforations in eardrum and expansion&#xD;
      of the disease process into the antrum, mastoid, attic and middle ear. Granulation tissue,&#xD;
      polyps and foul- smelling otorrhea are common findings in this type&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the Level of Middle Cranial Fossa Dura in Patients with Cholesteatoma by multislice computed tomography.</measure>
    <time_frame>One year</time_frame>
    <description>determination the level of tegmen in patients with attico-antral diseases by MSCT</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cholesteatoma, Middle Ear</condition>
  <arm_group>
    <arm_group_label>Patients with cholesteatoma</arm_group_label>
    <description>Patients with cholesteatoma in one ear that will compared with the other healthy one.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Multislice computed tomography temporal bone</intervention_name>
    <description>Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient</description>
    <arm_group_label>Patients with cholesteatoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cholesteatoma in one ear&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adults above the age of 18 presented to the Assiut university Clinic with&#xD;
&#xD;
        cholesteatoma will be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previous mastoid surgery&#xD;
&#xD;
          2. Patients with Craniofacial anomalies or cleft lip and palate&#xD;
&#xD;
          3. Pediatric populations â‰¤ 18 years old&#xD;
&#xD;
          4. Patients with congenital ear anomalies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mariam Zakaria</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholesteatoma, Middle Ear</mesh_term>
    <mesh_term>Cholesteatoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

